Amplification of antibody production by phosphorothioate oligodeoxynucleotides

被引:40
作者
Branda, RF
Moore, AL
Lafayette, AR
Mathews, L
Hong, R
Zon, G
Brown, T
McCormack, JJ
机构
[1] UNIV VERMONT,VERMONT CANC CTR,BURLINGTON,VT 05405
[2] LYNX THERAPEUT,HAYWARD,CA
[3] UNIV SOUTHAMPTON,DEPT CHEM,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND
[4] UNIV VERMONT,DEPT MED,BURLINGTON,VT 05405
[5] UNIV VERMONT,DEPT PEDIAT,BURLINGTON,VT 05405
[6] UNIV VERMONT,DEPT PHARMACOL,BURLINGTON,VT 05405
来源
JOURNAL OF LABORATORY AND CLINICAL MEDICINE | 1996年 / 128卷 / 03期
关键词
D O I
10.1016/S0022-2143(96)90035-9
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A phosphorothioate oligodeoxynucleotide that is complementary (antisense) to the initiation region of the rev gene of HIV-1 causes hypergammaglobulinemia and splenomegaly in mice, and it induces B cell proliferation and differentiation in mouse spleen mononuclear cells (SMNCs) and human peripheral blood mononuclear cells in vitro. The current studies were performed to investigate the specificity of these immunomodulatory effects. Both the sense and antisense rev oligomers stimulated tritiated thymidine incorporation and secretion of immunoglobulin M (IgM) and immunoglobulin G (IgG) by mouse SMNCs in a concentration-dependent fashion, but the antisense oligomer produced greater immune effects. Studies comparing phosphorothioate oligomers (anti-rev, c-myc, and c-myb) either methylated or unmethylated at CpG dinucleotides showed that methylation effectively abrogated the proliferative effect and tended to reduce the immunoglobulin secretary activity, but the latter was not statistically significant except in the case of IgG in anti-rev oligomer-treated cultures. Mice were injected with the sense or antisense rev oligomers singly or in combination. The animals then were immunized with tetanus toroid and received a booster 21 days later. Oligodeoxynucleotide-treated mice had significantly higher levels of IgM antibodies on days 28 and 35 and of IgG antibodies on days 14 and 35 as compared with mice that were immunized but received vehicle alone. There was no evidence for additive, synergistic, or antagonistic interactions of the sense and antisense rev oligomers. These results indicate that the unmethylated anti-rev oligomer is the most potent of the phosphorothioate oligomers tested at activating lymphocyte proliferation and differentiation and that a single intravenous injection of this oligodeoxynucleotide augments antibody production to a specific antigen as long as 35 days later.
引用
收藏
页码:329 / 338
页数:10
相关论文
共 30 条
  • [1] THE INDUCIBLE TRANSCRIPTION ACTIVATOR NF-KAPPA-B - REGULATION BY DISTINCT PROTEIN SUBUNITS
    BAEUERLE, PA
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1072 (01) : 63 - 80
  • [2] BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
  • [3] BISHOP MR, 1993, BLOOD, V82, pA443
  • [4] Branda R. F., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P455
  • [5] B-cell proliferation and differentiation in common variable immunodeficiency patients produced by an antisense oligomer to the rev gene of HIV-1
    Branda, RF
    Moore, AL
    Hong, R
    McCormack, JJ
    Zon, G
    CunninghamRundles, C
    [J]. CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 79 (02): : 115 - 121
  • [6] IMMUNE STIMULATION BY AN ANTISENSE OLIGOMER COMPLEMENTARY TO THE REV GENE OF HIV-1
    BRANDA, RF
    MOORE, AL
    MATHEWS, L
    MCCORMACK, JJ
    ZON, G
    [J]. BIOCHEMICAL PHARMACOLOGY, 1993, 45 (10) : 2037 - 2043
  • [7] THE ANTIPROLIFERATIVE ACTIVITY OF C-MYB AND C-MYC ANTISENSE OLIGONUCLEOTIDES IN SMOOTH-MUSCLE CELLS IS CAUSED BY A NONANTISENSE MECHANISM
    BURGESS, TL
    FISHER, EF
    ROSS, SL
    BREADY, JV
    QIAN, YX
    BAYEWITCH, LA
    COHEN, AM
    HERRERA, CJ
    HU, SSF
    KRAMER, TB
    LOTT, FD
    MARTIN, FH
    PIERCE, GF
    SIMONET, L
    FARRELL, CL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (09) : 4051 - 4055
  • [8] OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS
    COHEN, JS
    [J]. PHARMACOLOGY & THERAPEUTICS, 1991, 52 (02) : 211 - 225
  • [9] ERSHLER WB, 1982, CLIN EXP IMMUNOL, V49, P552
  • [10] FAKLER B, 1994, J BIOL CHEM, V269, P16187